OCGN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 23.55%, SMA50 22.49%, SMA200 47.6%). The stock’s 14-day RSI is 71.57 (overbought), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.59% below its high and over 263.11% above its low. Average 10-day trading volume of 14.62 million shares is significantly above the 3-month average of 6.25 million, indicating heightened recent market interest.

Ocugen, Inc. has 312.30 million shares outstanding. The public float is 287.94 million shares, elevated short interest at 19.04% of float. This equals 54.76 million shares. The short ratio is 13.59 days. Institutional investors hold 16.89% of the float. Insiders own 1.49%. Musunuri Shankar holds 2.19 million shares, KIRK RANDAL J has 1.69 million shares and Zhang Junge has 1.08 million shares.

Ocugen, Inc. generated EPS of -$0.22 over the past year. Five-year average earnings growth is 32.82%. Wall Street analysts project EPS growth of 44.07% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.06. Next year's EPS is expected at $3.42. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $7.00. The high target offers 303.23% upside. The low target suggests 182.26% downside. The mean target is $7.43. This offers 199.6% upside. Ocugen, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 14.71%. The prior quarter beat by -16.67%. Over the last six quarters, Apple has recorded several small beats. These include -1.05% in August 08, 2024.

Ocugen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.26. This means the shares are trading below this model’s fair value.

Ocugen, Inc. (NASDAQ:OCGN) closed at $2.48 USD, gaining $0.14 (5.98%) from the previous close of $2.34. The stock is currently mid-range between its 52-week high and low $0.52 and $2.67. With a market capitalization of about $813.18 million, Ocugen, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.90). Key stats such as the average daily volume over the past year has been around 6.44 million shares, trading with heavier-than-usual volume. Headquartered in Malvern, PA, Ocugen, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shankar Musunuri, the company employs approximately 95 people and listed since December 03, 2014. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.

Ocugen, Inc. trades at a P/E ratio of -11.42, slightly below the S&P 500 average, with a price-to-sales ratio of 184.27 and a price-to-book ratio of -63.67 indicating negative book value, which may reflect financial stress. The P/FCF stands at -14.23, also below market averages.

Ocugen, Inc. (NASDAQ:OCGN) shares are up 23.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ocugen, Inc. trading at a premium to the broader market with a P/E of -11.42. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $6.21, suggesting 150.4% upside. Our AI forecast model points to short-term strength (6.05% over two weeks), a medium-term rise (193.15% over three months), and a longer-term gain (1013.71% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Ocugen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.05%, with price expected at $2.63 by March 27, 2026, within a range of $2.47 to $2.79 3-Month Outlook: Projected rise of 193.15%, reaching $7.27 by June 11, 2026, with a range of $7.11 to $7.61. 1-Year Outlook: Projected gain of 1013.71%, with price at $27.62 by March 12, 2027, within a range of $28.72 to $33.27.